A meta-analysis of 19 randomized, controlled clinical studies that lasted at least 3 months indicates that long-acting beta-agonists (LABAs) more than double the rates at which asthma patients may become hospitalized.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Asthma patient hospitalization risk more than doubles with long-acting beta-agonist use of 3 months

Newsletter